Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis

Molecular and Cellular Biology

Volumn 26, Issue 21, 2006, Pages 8109-8121

  Jang, Joanne W ^a   Boxer, Robert B ^a   Chodosh, Lewis A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; GUANOSINE TRIPHOSPHATE; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYC PROTEIN; RAS PROTEIN; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CELL GROWTH; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXPERIMENTAL MOUSE; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE C MYC; ONCOGENE H RAS; ONCOGENE H RAS1; ONCOGENE KRAS2; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FEMALE; HUMANS; ISOENZYMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53; WNT1 PROTEIN;

EID: 33750379861     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00404-06     Document Type: Article

References (41)

1. Berger, M. S., G. W. Locher, S. Saurer, W. J. Gullick, M. D. Waterfield, B. Groner, and N. E. Hynes. 1988. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 48:1238-1243.
2. Biscardi, J. S., R. C. Ishizawar, C. M. Silva, and S. J. Parsons. 2000. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2:203-210.
3. Blancato, J., B. Singh, A. Liu, D. J. Liao, and R. B. Dickson. 2004. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br. J. Cancer 90:1612-1619.
4. Boxer, R. B., J. W. Jang, L. Sintasath, and L. A. Chodosh. 2004. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6:577-586.
5. Brown, A. M. 2001. Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res. 3:351-355.
6. Choi, J. A., M. T. Park, C. M. Kang, H. D. Um, S. Bae, K. H. Lee, T. H. Kim, J. H. Kim, C. K. Cho, Y. S. Lee, H. Y. Chung, and S. J. Lee. 2004. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways. Oncogene 23:9-20.
7. Clark, G. J., and C. J. Der. 1995. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res. Treat. 35:133-144.
8. D'Cruz, C. M., E. J. Gunther, R. B. Boxer, J. L. Hartman, L. Sintasath, S. E. Moody, J. D. Cox, S. I. Ha, G. K. Belka, A. Golant, R. D. Cardiff, and L. A. Chodosh. 2001. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7:235-239.
9. Deming, S. L., S. J. Nass, R. B. Dickson, and B. J. Track. 2000. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br. J. Cancer 83:1688-1695.
10. Devereux, T. R., W. Holliday, C. Anna, N. Ress, J. Roycroft, and R. C. Sills. 2002. Map kinase activation correlates with K-ras mutation and loss of heterozygosity on chromosome 6 in alveolar bronchiolar carcinomas from B6C3F1 mice exposed to vanadium pentoxide for 2 years. Carcinogenesis 23:1737-1743.
11. Felsher, D. W., and J. M. Bishop. 1999. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. USA 96:3940-3944.
12. Guerra, C., N. Mijimolle, A. Dhawahir, P. Dubus, M. Barradas, M. Serrano, V. Campuzano, and M. Barbacid. 2003. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4:111-120.
13. Gunther, E. J., G. K. Belka, G. B. Wertheim, J. Wang, J. L. Hartman, R. B. Boxer, and L. A. Chodosh. 2002. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J. 16:283-292.
14. Gunther, E. J., S. E. Moody, G. K. Belka, K. T. Hahn, N. Innocent, K. D. Dugan, R. D. Cardiff, and L. A. Chodosh. 2003. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17:488-501.
15. Guzman, R. C., R. C. Osborn, S. M. Swanson, R. Sakthivel, S. I. Hwang, S. Miyamoto, and S. Nandi. 1992. Incidence of c-Ki-ras activation in N-methyl-N-nitrosourea-induced mammary carcinomas in pituitary-isografted mice. Cancer Res. 52:5732-5737.
16. Hwang, S. I., R. C. Guzman, S. M. Swanson, and S. Nandi. 1996. Hormone dependent and independent mammary tumor development form N-methyl-N-nitrosourea- treated rat mammary epithelial cell xenografts in the nude mouse: multiple pathways and H-ras activation. Cancer Lett. 101:123-134.
17. Ibrahim, Y. H., and D. Yee. 2005 Insulin-like growth factor-I and breast cancer therapy. Clin. Cancer Res. 11:944s-950s.
18. Johnson, L., K. Mercer, D. Greenbaum, R. T. Bronson, D. Crowley, D. A. Tuveson, and T. Jacks. 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111-1116.
19. Land, H., L. F. Parada, and R. A. Weinberg. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596-602.
20. Liao, D. J., and R. B. Dickson. 2000. c-Myc in breast cancer. Endocr. Relat. Cancer 7:143-164.
21. Lin, S. Y., W. Xia, J. C. Wang, K. Y. Kwong, B. Spohn, Y. Wen, R. G. Pestell, and M. C. Hung. 2000. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA 97:4262-4266.
22. Liu, M. L., F. C. Von Lintig, M. Liyanage, M. A. Shibata, C. L. Jorcyk, T. Ried, G. R. Boss, and J. E. Green. 1998. Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene 17:2403-2411.
23. Marquis, S. T., J. V. Rajan, A. Wynshaw-Boris, J. Xu, G. Y. Yin, K. J. Abel, B. L. Weber, and L. A. Chodosh. 1995. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat. Genet. 11:17-26.
24. Miyakis, S., G. Sourvinos, and D. A. Spandidos. 1998. Differential expression and mutation of the ras family genes in human breast cancer. Biochem. Biophys. Res. Commun. 251:609-612.
25. Miyamoto, S., S. Sukumar, R. C. Guzman, R. C. Osborn, and S. Nandi. 1990. Transforming c-Ki-ras mutation is a preneoplastic event in mouse mammary carcinogenesis induced in vitro by N-methyl-N-nitrosourea. Mol. Cell. Biol. 10:1593-1599.
26. Moon, A., M. S. Kim, T. G. Kim, S. H. Kim, H. E. Kim, Y. Q. Chen, and H. R. Kim. 2000. H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int. J. Cancer 85:176-181.
27. Nusse, R., and H. E. Varmus. 1982. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31:99-109.
28. Podsypanina, K., Y. Li, and H. E. Varmus. 2004. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype. BMC Med. 2:24.
29. Rochlitz, C. F., G. K. Scott, J. M. Dodson, E. Liu, C. Dollbaum, H. S. Smith, and C. C. Benz. 1989. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res. 49: 357-360.
30. Schlotter, C. M., U. Vogt, U. Bosse, B. Mersch, and K. Wassmann. 2003. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res. 5:R30-R36.
31. Schondorf, T., A. Andrack, D. Niederacher, A. Scharl, M. Becker, H. Engel, and U. J. Gohring. 1999. H-ras gene amplification or mutation is not common in human primary breast cancer. Oncol. Rep. 6:1029-1033.
32. Sinn, E., W. Muller, P. Pattengale, I. Tepler, R. Wallace, and P. Leder. 1987. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49:465-475.
33. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
34. Surmacz, E. 2000. Function of the IGF-I receptor in breast cancer. J. Mammary Gland Biol. Neoplasia 5:95-105.
35. Swanson, S. M., R. C. Guzman, K. Christov, S. Miyamoto, and S. Nandi. 1994. Pituitary-isografted mice are highly susceptible to MNU-induced mammary carcinogenesis irrespective of the level of alveolar differentiation. Carcinogenesis 15:1341-1346.
36. Tuveson, D. A., A. T. Shaw, N. A. Willis, D. P. Silver, E. L. Jackson, S. Chang, K. L. Mercer, R. Grochow, H. Hock, D. Crowley, S. R. Hingorani, T. Zaks, C. King, M. A. Jacobetz, L. Wang, R. T. Bronson, S. H. Orkin, R. A. DePinho, and T. Jacks. 2004. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5:375-387.
37. Voice, J. K., R. L. Klemke, A. Le, and J. H. Jackson. 1999. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J. Biol. Chem. 274:17164-17170.
38. von Lintig, F. C., A. D. Dreilinger, N. M. Varki, A. M. Wallace, D. E. Casteel, and G. R. Boss. 2000. Ras activation in human breast cancer. Breast Cancer Res. Treat. 62:51-62.
39. Wu, Y., C. A. Renard, F. Apiou, M. Huerre, P. Tiollais, B. Dutrillaux, and M. A. Buendia. 2002. Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors. Oncogene 21:1518-1526.
40. Van, J., S. Roy, A. Apolloni, A. Lane, and J. F. Hancock. 1998. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. 273:24052-24056.
41. Zhang, Z., Y. Wang, H. G. Vikis, L. Johnson, G. Liu, J. Li, M. W. Anderson, R. C. Sills, H. L. Hong, T. R. Devereux, T. Jacks, K. L. Guan, and M. You. 2001. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 29:25-33.